Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)
China
· Delayed Price · Currency is CNY 10.72
+0.17 (1.61%)
Apr 30, 2025, 3:00 PM CST
SHA:603567 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2014 - 2018 |
| Net Income | 653.39 | 472.74 | 185.44 | 332.1 | 436.29 | 408.65 | Upgrade
|
| Depreciation & Amortization | 184.33 | 184.33 | 169 | 137.1 | 155.89 | 138.42 | Upgrade
|
| Other Amortization | 16.85 | 16.85 | 12.18 | 17.78 | 21.64 | 19.41 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.26 | 0.26 | -39.52 | 0.89 | 0.11 | 0.03 | Upgrade
|
| Asset Writedown & Restructuring Costs | 3.91 | 3.91 | 1.47 | 0.3 | 0.11 | 0.07 | Upgrade
|
| Loss (Gain) From Sale of Investments | -464.47 | -464.47 | -24.73 | -242.67 | -20.32 | 3.73 | Upgrade
|
| Provision & Write-off of Bad Debts | 3.84 | 3.84 | -29.8 | 44.34 | 35.38 | 18.68 | Upgrade
|
| Other Operating Activities | 193.35 | 233.95 | 162.63 | 211.71 | 155.78 | 170.48 | Upgrade
|
| Change in Accounts Receivable | -891.41 | -891.41 | 107.18 | -1,233 | -548.8 | -746.15 | Upgrade
|
| Change in Inventory | 282.66 | 282.66 | -270.89 | 381.02 | -217.01 | 532.08 | Upgrade
|
| Change in Accounts Payable | -277.49 | -277.49 | -521.86 | -74.84 | 170.89 | -337.3 | Upgrade
|
| Change in Other Net Operating Assets | - | - | 0.62 | -0.87 | - | - | Upgrade
|
| Operating Cash Flow | -338.19 | -478.24 | -326.79 | -433.94 | 155.18 | 220.92 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | - | -29.76% | -39.87% | Upgrade
|
| Capital Expenditures | 41.01 | -95.14 | -404.27 | -448.63 | -868.65 | -178.79 | Upgrade
|
| Sale of Property, Plant & Equipment | 91.12 | 129.45 | 0.64 | 3.7 | 0.87 | 0.12 | Upgrade
|
| Cash Acquisitions | - | - | -17.51 | - | - | - | Upgrade
|
| Divestitures | -63.31 | 94.87 | 369.74 | 373 | 50 | - | Upgrade
|
| Investment in Securities | -95.15 | -53 | 222.9 | -757.24 | -636.85 | -82.1 | Upgrade
|
| Other Investing Activities | 130 | 100.25 | 112.44 | 407.91 | 3.74 | - | Upgrade
|
| Investing Cash Flow | 103.66 | 176.43 | 283.93 | -421.26 | -1,451 | -260.76 | Upgrade
|
| Long-Term Debt Issued | - | 2,655 | 1,680 | 860 | 2,140 | 2,526 | Upgrade
|
| Total Debt Issued | 1,930 | 2,655 | 1,680 | 860 | 2,140 | 2,526 | Upgrade
|
| Long-Term Debt Repaid | - | -2,441 | -1,724 | -1,138 | -1,618 | -1,990 | Upgrade
|
| Total Debt Repaid | -1,856 | -2,441 | -1,724 | -1,138 | -1,618 | -1,990 | Upgrade
|
| Net Debt Issued (Repaid) | 74.05 | 214.05 | -44.4 | -278.12 | 522.11 | 535.89 | Upgrade
|
| Issuance of Common Stock | 199.25 | 219.68 | - | 1,228 | 101 | 47.51 | Upgrade
|
| Repurchase of Common Stock | - | - | -29.99 | - | - | - | Upgrade
|
| Common Dividends Paid | -324.58 | -158.28 | -243.55 | -143.73 | -332.22 | -251.81 | Upgrade
|
| Other Financing Activities | 448.38 | 490.24 | -101 | -8.7 | 1.21 | -2.77 | Upgrade
|
| Financing Cash Flow | 397.1 | 765.69 | -418.94 | 797.46 | 292.11 | 328.82 | Upgrade
|
| Net Cash Flow | 162.56 | 463.87 | -461.81 | -57.74 | -1,004 | 288.98 | Upgrade
|
| Free Cash Flow | -297.18 | -573.38 | -731.07 | -882.57 | -713.47 | 42.14 | Upgrade
|
| Free Cash Flow Margin | -9.53% | -18.27% | -17.35% | -21.39% | -20.96% | 1.28% | Upgrade
|
| Free Cash Flow Per Share | -0.32 | -0.61 | -0.78 | -1.02 | -0.84 | 0.05 | Upgrade
|
| Cash Income Tax Paid | 381.16 | 380.65 | 201.36 | 429.61 | 436.47 | 381.58 | Upgrade
|
| Levered Free Cash Flow | -597.32 | -746.75 | -404.69 | -881.7 | -1,337 | -13.98 | Upgrade
|
| Unlevered Free Cash Flow | -511.13 | -662.12 | -318.01 | -791.21 | -1,244 | 57.07 | Upgrade
|
| Change in Net Working Capital | 1,184 | 886.34 | -40.53 | 666.44 | 918.44 | 275.99 | Upgrade
|
Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.